Anthony GONCALVES
Institut Paoli-Calmettes
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anthony GONCALVES as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:27 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05143970 · A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid TumorsInstitut Paoli-Calmettes · active not recruiting · Metastatic Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer · principal investigator
- Ph2NCT03515798 · Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast CancerInstitut Paoli-Calmettes · active not recruiting · Inflammatory Breast Cancer · principal investigator
- Ph1/Ph2NCT01980277 · Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast CancerInstitut Paoli-Calmettes · terminated · Breast Cancer · principal investigator
- Ph1/Ph2NCT01589861 · Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast CancerInstitut Paoli-Calmettes · terminated · Breast Cancer · principal investigator
- Ph1NCT00908869 · Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b (" Metronomic Chemotherapy ") for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced NeoplasmInstitut Paoli-Calmettes · completed · Advanced Neoplasm · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:27 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:27 UTC. The ranking covers the 200 most relevant of 140 PubMed records, and a shared surname and initials can bring in a namesake. All 140 on PubMed
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.N Engl J Med · 20181,734 citationsRCR 58.5
- 866 citationsRCR 22.7
- Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.Lancet Oncol · 2013597 citationsRCR 16.2
- Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.Lancet Oncol · 2021432 citationsRCR 21.2
- 363 citationsRCR 14.5
- Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.N Engl J Med · 2016345 citationsRCR 11.2
- Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).Lancet Oncol · 2014309 citationsRCR 7.2
- The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.Lancet Infect Dis · 2015235 citationsRCR 7.2
- 231 citationsRCR 7.1
- Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.J Immunother Cancer · 2021190 citationsRCR 9.3